Aurobindo Pharma: The financial results for the period ended September 30, 2026
Aurobindo Pharma (AUROPHARMA) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹98,102 crore.
What happened
Aurobindo Pharma (AUROPHARMA) filed a disclosure with the exchanges on 4 November 2026 at 07:53 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Aurobindo Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹98,102 crore.
The stock last traded at ₹1,705, against a 52-week range of ₹1,106–₹1,740 (2.0% below the high).
Before this filing the shares had moved +1.1% over the month and +6.8% over three months. Average daily turnover over the last 20 sessions was about ₹137 crore.
Promoters held 51.88% at the end of Q1 FY27, up 0.06% points from the previous quarter; 13.75% of promoter shares were pledged. Foreign institutions owned 16.38% and domestic institutions 25.10%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 7,868 | 824.8 | 14.2 |
| Q2 FY26 | 8,286 | 848.5 | 14.61 |
| Q3 FY26 | 8,646 | 910.3 | 15.67 |
| Q4 FY26 | 8,853 | 921.3 | 15.86 |
| Q1 FY27 | 9,150 | 1,032.6 | 17.86 |
What history shows
This is not the company's first results disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 2.8% on average the next trading day and was up 3.1% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +2.0% over five days; 57% of them rose the next day.
Market-wide, 10,790 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 5 Aug 2026 | A press release dated August 05, 2026, titled "Press Release on… | +2.8% | +3.1% |
| 5 Aug 2026 | , the financial results for the period ended Jun 30, 2026. | +2.8% | +3.1% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 4 November 2026: Board meeting — Financial Results/Dividend.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.